Sustained Drug-Drug Interaction Between Cyclosporine and Apalutamide in a Patient With Metastatic Hormone-Sensitive Prostate Cancer: A Case Report and Evaluation of CYP3A4 Induction via Pregnane X Receptor Activation by Apalutamide.
Saved in:
| Title: | Sustained Drug-Drug Interaction Between Cyclosporine and Apalutamide in a Patient With Metastatic Hormone-Sensitive Prostate Cancer: A Case Report and Evaluation of CYP3A4 Induction via Pregnane X Receptor Activation by Apalutamide. |
|---|---|
| Authors: | Mimura Y; Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan, nagoya-cu.ac.jp., Sanda T; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan, nagoya-cu.ac.jp., Unno R; Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan, nagoya-cu.ac.jp., Furukawa Y; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan, nagoya-cu.ac.jp., Shizu R; Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Shizuoka, Japan, u-shizuoka-ken.ac.jp., Motokatsu K; Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Shizuoka, Japan, u-shizuoka-ken.ac.jp., Tashiro Y; Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan, nagoya-cu.ac.jp., Tasaki Y; Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan, nagoya-cu.ac.jp., Sugiyama Y; Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan, nagoya-cu.ac.jp., Yasujima T; Department of Biopharmaceutics, Nagoya City University Graduate School of Pharmaceutical Sciences, Nagoya, Aichi, Japan., Naiki T; Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan, nagoya-cu.ac.jp., Horita Y; Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan, nagoya-cu.ac.jp., Hotta Y; Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan, nagoya-cu.ac.jp., Yuasa H; Department of Biopharmaceutics, Nagoya City University Graduate School of Pharmaceutical Sciences, Nagoya, Aichi, Japan., Yoshinari K; Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Shizuoka, Japan, u-shizuoka-ken.ac.jp., Yasui T; Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan, nagoya-cu.ac.jp., Iida S; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan, nagoya-cu.ac.jp., Furukawa-Hibi Y; Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan, nagoya-cu.ac.jp. |
| Source: | Case reports in oncological medicine [Case Rep Oncol Med] 2026 Feb 24; Vol. 2026, pp. 3539500. Date of Electronic Publication: 2026 Feb 24 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101581035 Publication Model: eCollection Cited Medium: Print ISSN: 2090-6706 (Print) NLM ISO Abbreviation: Case Rep Oncol Med Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
